Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab

Authors

J. Gillen, University of Oklahoma Health Sciences Center
K. A. Mills, Washington University School of Medicine in St. Louis
J. Dvorak, University of Oklahoma Health Sciences Center
B. Zheng, University of Oklahoma Norman Campus
T. Thai, University of Oklahoma Health Sciences Center
R. Salani, The Ohio State University
C. M. Cosgrove, The Ohio State University
B. Davidson, Duke University
P. H. Thaker, Washington University School of Medicine in St. Louis
K. N. Moore, University of Oklahoma Health Sciences Center

Journal

Gynecologic Oncology Reports

Publication Date

2019

Volume

30

First Page

100502

Document Type

Open Access Publication

DOI

10.1016/j.gore.2019.100502

Rights and Permissions

Gillen J, Mills KA, Dvorak J, Zheng B, Thai T, Salani R, Cosgrove CM, Davidson B, Thaker PH, Moore KN (2019) Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab. Gynecologic Oncology Reports, 30: 100502. DOI: 10.1016/j.gore.2019.100502 © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

Recommended Citation

Gillen, J.; Mills, K. A.; Dvorak, J.; Zheng, B.; Thai, T.; Salani, R.; Cosgrove, C. M.; Davidson, B.; Thaker, P. H.; and Moore, K. N., "Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab." Gynecologic Oncology Reports. 30, 100502 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8441